Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
- PMID: 10604467
- DOI: 10.1038/45159
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Abstract
Cyclin-dependent kinase 5 (Cdk5) is required for proper development of the mammalian central nervous system. To be activated, Cdk5 has to associate with its regulatory subunit, p35. We have found that p25, a truncated form of p35, accumulates in neurons in the brains of patients with Alzheimer's disease. This accumulation correlates with an increase in Cdk5 kinase activity. Unlike p35, p25 is not readily degraded, and binding of p25 to Cdk5 constitutively activates Cdk5, changes its cellular location and alters its substrate specificity. In vivo the p25/Cdk5 complex hyperphosphorylates tau, which reduces tau's ability to associate with microtubules. Moreover, expression of the p25/Cdk5 complex in cultured primary neurons induces cytoskeletal disruption, morphological degeneration and apoptosis. These findings indicate that cleavage of p35, followed by accumulation of p25, may be involved in the pathogenesis of cytoskeletal abnormalities and neuronal death in neurodegenerative diseases.
Comment in
-
Alzheimer's disease. The tangled tale of tau.Nature. 1999 Dec 9;402(6762):588-9. doi: 10.1038/45095. Nature. 1999. PMID: 10604460 No abstract available.
Similar articles
-
Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.Neuron. 2003 Oct 30;40(3):471-83. doi: 10.1016/s0896-6273(03)00627-5. Neuron. 2003. PMID: 14642273
-
Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain.Neurosci Lett. 2001 Jun 22;306(1-2):37-40. doi: 10.1016/s0304-3940(01)01864-x. Neurosci Lett. 2001. PMID: 11403952
-
Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.Biochem Biophys Res Commun. 2002 Nov 15;298(5):693-8. doi: 10.1016/s0006-291x(02)02543-3. Biochem Biophys Res Commun. 2002. PMID: 12419309
-
The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.Neurosignals. 2003 Sep-Oct;12(4-5):221-9. doi: 10.1159/000074624. Neurosignals. 2003. PMID: 14673209 Review.
-
Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.Biotechnol J. 2007 Aug;2(8):978-87. doi: 10.1002/biot.200700057. Biotechnol J. 2007. PMID: 17526058 Review.
Cited by
-
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.Int J Mol Sci. 2021 Mar 10;22(6):2806. doi: 10.3390/ijms22062806. Int J Mol Sci. 2021. PMID: 33802080 Free PMC article. Review.
-
Synaptic therapy in Alzheimer's disease: a CREB-centric approach.Neurotherapeutics. 2015 Jan;12(1):29-41. doi: 10.1007/s13311-014-0327-5. Neurotherapeutics. 2015. PMID: 25575647 Free PMC article. Review.
-
Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease.Mol Neurobiol. 2021 Aug;58(8):4122-4133. doi: 10.1007/s12035-021-02400-2. Epub 2021 May 3. Mol Neurobiol. 2021. PMID: 33939165 Free PMC article.
-
Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.Drug Discov Today. 2017 Feb;22(2):223-233. doi: 10.1016/j.drudis.2016.10.010. Epub 2016 Oct 27. Drug Discov Today. 2017. PMID: 27794478 Free PMC article. Review.
-
Cyclin-Dependent kinase 5 targeting prevents β-Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases.J Neurosci Res. 2015 Aug;93(8):1258-66. doi: 10.1002/jnr.23576. Epub 2015 Feb 24. J Neurosci Res. 2015. PMID: 25711385 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials